WHAT IS CLAIMED IS:

1. A compound of Formula *I*:



I

or a pharmaceutically-acceptable salt or solvate thereof, wherein:

n is an integer from zero to 3;

p is an integer from 2 to 4;

X is -N=, -NH- or -S-;

Y is oxygen or sulfur;

each occurrence of R_1 is independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, amino, nitro and cyano;

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl; or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-, wherein each occurrence of R_5 is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} hydroxyalkyl; and

R_4 is selected from the group consisting of:

(i)



wherein:

Z is -O-, -S-, -NH-, $-CH_2-$, $-NHCH_2-$, $-CH_2NH-$, $-OCH_2-$, $-CH_2O-$, $-SCH_2-$ or $-CH_2S-$;

each occurrence of R_6 is independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxyalkyl; and

q is an integer from zero to 4;

(ii)



wherein:

each occurrence of R_7 and each occurrence of R_8 are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl and C_{1-6} alkoxyalkyl;

r is an integer from zero to 4; and

s is an integer from zero to 4;

(iii)



wherein:

R_9 is hydrogen, halogen or alkyl,

provided that when R_9 is hydrogen, neither R_2 nor R_3 is hydrogen or C_{1-6} alkyl;

(iv)



wherein:

R_{10} is hydrogen or alkyl;

and

(v) naphthyl.

2. The compound according to claim 1, wherein *n* is zero.

3. The compound according to claim 1, wherein *p* is 2.

4. The compound according to claim 1, wherein Y is oxygen.

5. The compound according to claim 1, wherein R_2 and R_3 together with the nitrogen to which they are attached form a piperidyl ring.

6. The compound according to claim 1, wherein R_4 is moiety (i).

7. The compound according to claim 6, wherein the R_4 moiety is attached to the bicyclic benzoheterocyclic core *meta* or *para* relative to Z.

8. The compound according to claim 6, wherein Z is -O-, $-OCH_2-$ or $-CH_2O-$.

9. The compound according to claim 6, wherein *q* is zero, 1 or 2.

10. The compound according to claim 6, wherein R_6 is halogen, C_{1-4} alkyl or C_{1-4} haloalkyl.

11. The compound according to claim 6, wherein R_4 is 4-(4-fluorophenoxy)phenyl, 3-(3,4-dichlorophenoxy)phenyl, 3-(3-trifluoromethylphenoxy)phenyl, 3-benzyloxyphenyl or 3-(4-*tert*-butylphenoxy)phenyl.

12. The compound according to claim 1, wherein R_4 is moiety (ii).

13. The compound according to claim 12, wherein *r* is zero.

14. The compound according to claim 12, wherein *s* is zero.

15. The compound according to claim 12, wherein R_7 and R_8 are independently selected from the group consisting of halogen, C_{1-4} alkyl and C_{1-4} haloalkyl.

16. The compound according to claim 12, wherein R_4 is 2,2-diphenylethenyl.

17. The compound according to claim 1, wherein:
X is -NH-;
Y is oxygen; and
R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-.

18. The compound according to claim 1, wherein:
X is -NH-;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_5-$; and

R_4 is either of moieties (i) or (ii).

19. The compound according to claim 1, wherein:

X is -NH-;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and $-NR_5-$; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

20. The compound according to claim 1, wherein:

X is -N=;

Y is oxygen; and

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_5-$.

21. The compound according to claim 1, wherein:

X is -N=;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_5-$; and

R_4 is either of moieties (i) or (ii).

22. The compound according to claim 1, wherein:

X is -N=;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and $-NR_5-$; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

23. The compound according to claim 1, wherein:

X is -S-;

Y is oxygen; and

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_5-$.

24. The compound according to claim 1, wherein:

X is -S-;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is either of moieties (i) or (ii).

25. The compound according to claim 1, wherein:

X is -S-;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

26. A compound selected from the group consisting of

2-(2,2-diphenylethenyl)-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1*H*-quinazolin-4-one;

2-[4-(4-fluorophenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1*H*-quinazolin-4-one;

2-[3-(3,4-dichlorophenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1*H*-quinazolin-4-one;

2-[3-(3-trifluoromethylphenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydro-1*H*-quinazolin-4-one;

2-(2,2-diphenylethenyl)-3-(2-piperidin-1-ylethyl)-benzopyrimidin-4-one;

2-[4-(4-fluorophenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-benzo-pyrimidin-4-one;

2-[3-(3-trifluoromethylphenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-benzopyrimidin-4-one;

2-(3-benzyloxy)phenyl-3-(2-piperidin-1-ylethyl)-2,3-dihydrobenzo-1,3-thiazin-4-one;

2-[3-(3-trifluoromethylphenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydrobenzo-1,3-thiazin-4-one;

2-[3-(4-*tert*-butylphenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydrobenzo-1,3-thiazin-4-one;

2-[4-(4-fluorophenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydro-benzo-1,3-thiazin-4-one;

2-(2,2-diphenylethenyl)-3-(2-piperidin-1-ylethyl)-2,3-dihydrobenzo-1,3-thiazin-4-one; and

2-[3-(3,4-dichlorophenoxy)phenyl]-3-(2-piperidin-1-ylethyl)-2,3-dihydrobenzo-1,3-thiazin-4-one;

or a pharmaceutically-acceptable salt or solvate thereof.

27. A pharmaceutical composition comprising the compound according to claim 1, or pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.

28. A method of making the compound according to claim 1 wherein X is -NH-, said method comprising:

(a) reacting a 2-nitrobenzoylchloride or a 2-nitrothiobenzoyl-chloride with a compound of Formula II:



II

wherein p, R_2 and R_3 are as defined in claim 1;

(b) reducing the product from (a) in the presence of hydrogen;

(c) reacting the product from (b) with an aldehyde of Formula III:



III

wherein R_4 is as defined in claim 1; and

(d) recovering the product obtained from (c).

29. A method of making the compound according to claim 1 wherein X is -N=, said method comprising:

(a) reacting a 2-nitrobenzoylchloride or a 2-nitrothiobenzoyl-chloride with a compound of Formula II:



II

wherein p, R_2 and R_3 are as defined in claim 1;

(b) reducing the product from (a) in the presence of hydrogen;

(c) reacting the product from (b) with an aldehyde of Formula III:



III

wherein R_4 is as defined in claim 1;

(d) reacting the product from (c) with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and trichloromethane; and

(e) recovering the product obtained from (d).

30. A method of making the compound according to claim 1 wherein X is -S-, said method comprising:

(a) reacting a 2-mercaptobenzoic acid or a 2-mercaptothiobenzoic acid with:

(i) a compound of Formula II:



II

wherein *p*, R_2 and R_3 are as defined in claim 1; and

(ii) an aldehyde of Formula III;



III

wherein R_4 is as defined in claim 1; and

(b) recovering the product obtained from (a).

31. A method of treating a mammal suffering from a disorder responsive to blockage of sodium channels, said method comprising administering to said mammal, in an amount that is effective for treating or ameliorating said disorder, a compound
of Formula *I*:



I

or a pharmaceutically-acceptable salt or solvate thereof, wherein:

n is an integer from zero to 3;

p is an integer from 2 to 4;

X is -N=, -NH- or -S-;

Y is oxygen or sulfur;

each occurrence of R_1 is independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, amino, nitro and cyano;

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl; or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-, wherein each occurrence of R_5 is independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl and C_{1-6} hydroxyalkyl; and

R_4 is selected from the group consisting of:

(i)



wherein:

Z is -O-, -S-, -NH-, -CH_2-, -$NHCH_2$-, -CH_2NH-, -OCH_2-, -CH_2O-, -SCH_2- or -CH_2S-;

each occurrence of R_6 is independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxyalkyl; and

q is an integer from zero to 4;

(ii)



wherein:

each occurrence of R_7 and each occurrence of R_8 are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl and C_{1-6} alkoxyalkyl;

r is an integer from zero to 4; and

s is an integer from zero to 4;

(iii)



wherein:

R_9 is hydrogen, halogen or alkyl;

(iv)



wherein:

R_{10} is hydrogen or alkyl;

and

(v) naphthyl.

32. The method according to claim 31, wherein:

X is -NH-;

Y is oxygen; and

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring

optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-.

33. The method according to claim 31, wherein:

X is -NH-;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is either of moieties (i) or (ii).

34. The method according to claim 31, wherein:

X is -NH-;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

35. The method according to claim 31, wherein:

X is -N=;

Y is oxygen; and

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring

optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-.

36. The method according to claim 31, wherein:

X is -N=;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is either of moieties (i) or (ii).

37. The method according to claim 31, wherein:

X is -N=;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

38. The method according to claim 31, wherein:

X is -S-;

Y is oxygen; and

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkyloxy(C_{1-6})alkyl, or R_2 and R_3 together with the nitrogen atom to which they are attached form a ring having 3 to 7 carbon atoms, which ring

optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-.

39. The method according to claim 31, wherein:

X is -S-;

n is zero or 1;

Y is oxygen;

p is 2 or 3;

R_2 and R_3 are independently hydrogen or C_{1-6} alkyl, or R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is either of moieties (i) or (ii).

40. The method according to claim 31, wherein:

X is -S-;

n is zero;

Y is oxygen;

p is 2;

R_2 and R_3 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom selected from the group consisting of -O-, -S- and -NR_5-; and

R_4 is moiety (i) wherein Z is -O-, or R_4 is moiety (ii).

41. The method according to claim 31, wherein said disorder is selected from the group consisting of: neuronal damage, acute or chronic pain, neuropathic pain, surgical pain, convulsions, a neurodegenerative condition, manic depression and diabetic neuropathy.

42. The method according to claim 31, wherein said disorder is acute or chronic pain.

43. The method according to claim 31, wherein said disorder is neuropathic pain.

44. The method according to claim 31, wherein said disorder is surgical pain.

45. The method according to claim 31, wherein said disorder is neuronal damage caused by focal or global ischemia.

46. The method according to claim 31, wherein said disorder is a neurodegenerative condition.

47. The method according to claim 46, wherein said neurodegenerative condition is amyotrophic lateral sclerosis (ALS).

48. The method according to claim 31, wherein said compound functions as an antitinnitus agent, an anticonvulsant, an antiarrhythmic, a local anesthetic or an antimanic depressant.

49. The method according to claim 31, wherein said mammal is a human, dog or cat.

50. The method according to claim 31, wherein said mammal is a human.